<DOC>
	<DOCNO>NCT00075062</DOCNO>
	<brief_summary>Microbicides drug destroy microbes virus bacteria . Rectal microbicides may able prevent transmission HIV anal intercourse . The purpose study obtain rectal sample men learn information may valuable future clinical trial rectal microbicides .</brief_summary>
	<brief_title>A Study Male Rectal Samples Preparation Future Rectal Microbicide Trials</brief_title>
	<detailed_description>Rectal microbicides prevent HIV transmission currently develop hope someday widely use prevent sexually transmit HIV . This study examine variable male rectal tissue ; information may useful future rectal microbicide safety efficacy study . The study evaluate difference rectal tissue HIV infect uninfected male either engage anal-receptive sex ( men sleep men , MSM ) anal-receptive sex . The study last approximately 7 month , 6 week follow-up . There four group study . Groups 1 2 enroll HIV uninfected men ; Groups 3 4 enroll HIV infect men . Groups 1 , 3 , 4 comprise MSM engage anal-receptive sex ; Group 2 comprise men . Patients provide medical medication history , undergo complete physical exam , receive HIV counsel screen . An anoscopy ( examination anus , anal canal , low rectum ) blood draw conduct screening , study entry , Weeks 2 4 . Rectal secretion collect sigmoidoscopy ( internal examination rectum , distal sigmoid colon , large bowel use small camera ) perform study entry Weeks 2 4 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Inclusion Criteria All Participants : HIV status confirm ELISA/Western Blot screen CD4 count great 200 cells/mm3 screen Able willing communicate English Able willing provide adequate information locator purpose Inclusion Criteria Men Practicing AnalReceptive Sex ( Groups 1 , 3 4 ) : Engaged analreceptive sex average least week 2 month prior study entry Agree refrain anal intercourse 24 hour prior one week sigmoidoscopy Inclusion Criteria Men Not Practicing AnalReceptive Sex ( Group 2 ) No history anal receptive intercourse 2 month prior study entry Inclusion Criteria HIV Infected Men ( Groups 3 4 ) : Viral load either great 10,000 copy RNA/ml plasma le 50 copy RNA/ml plasma least 2 month prior study entry Have change antiretroviral therapy within 6 week prior study entry For HIV infect patient , 3 HSV2 ( herpes ) outbreaks 12 month prior screen 1 HSV2 outbreak 6 month prior screen Active , serious infection ( HIV ) require parenteral antibiotic therapy within 15 day prior screen Inflammatory bowel disease ( ulcerative colitis Crohn 's disease ) rectal cancer Rectal surgery , include fistulectomy Diagnosed bleed disorder , include hemophilia , thrombocytopenia , impair blood clotting , current use anticoagulant , opinion investigator , would make participation study unsafe complicate interpretation study outcome data Prosthetic heart valve diagnosis valve abnormality Hemorrhoid surgery 6 month prior screen Bleeding hemorrhoid screen 6 week prior study entry Anal fistula 6 week prior study entry Active diarrheal disease ( great 3 time day ) bleed disorder Rectal culture positive chlamydia gonorrhea screen within 1 month prior study entry Unprotected anal intercourse 3 month prior study entry Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply study requirement Enrolled clinical trial duration participation HPTN 056</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
</DOC>